Shandong Boan Biotechnology Co., Ltd. (6955.HK)
HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
At close: 04:08PM HKT
| Previous Close | 9.260 |
| Open | 9.440 |
| Bid | 9.180 x N/A |
| Ask | 9.260 x N/A |
| Day's Range | 9.020 - 9.310 |
| 52 Week Range | 8.800 - 24.200 |
| Volume | |
| Avg. Volume | 232,265 |
| Market Cap | 4.716B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.250 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.24 |
PR NewswireBoan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA): one is BA1105, an innovative antibody; and the other is BA1301, an innovative Antibody-Drug Conjugate (ADC).
PR NewswireFirst Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection
Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) in China has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China.
© 2024 Yahoo. All rights reserved.